Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cappella has started patient enrollment in a multi-centre, open-label Italian study, which will evaluate Sideguard stent for the treatment of coronary artery disease (CAD).
Subscribe to our email newsletter
The study will assess the benefits of Sideguard stent as primary intervention, for managing bifurcation related coronary artery disease.
The Sideguard stent is designed to preserve the sidebranch of diseased coronary arteries by protecting the ostium, while minimising plaque shift.
Principal Investigator of the study, Giuseppe Massimo Sangiorgi said the shape and elastic properties of the nitinol Sideguard stent provide constant outward radial force on the lumen and ostium, providing support and protection to the side branch over time.